Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00459667 · ClinicalTrials.gov registry record · Phase 3
BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose
A Phase 3 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,420
- Enrollment target
NCT00459667: Completed Phase 3 study, sponsored by Bayer.
NCT00459667 is a Phase 3 study that has completed, run by Bayer. The registered enrollment target is 1,420 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (84% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00459667, a Phase 3 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,420 participants
- Enrollment target
Study Summary
The BEYOND Follow-Up study will give patients who participated in the preceding BEYOND study the opportunity to continue treatment with the 500µg dose of interferon beta (IFNB) 1b and will further investigate the safety and tolerability profile of interferon beta 1b 500µg during longer-term treatment.
Primary Outcome
The variable "Flu-like-syndrome" will consist of a combination of MedDRA terms (Preferred Terms and Lower Level Terms) indicative for this condition.
Interventions
- DRUG Interferon beta-1b (Betaseron, BAY86-5046)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,420 participants |
| Start Date | 2007-05 |
| Est. Completion | 2008-03 |
| Phase | Phase 3 |
What the finished NCT00459667 record still lists
NCT00459667 is an interventional study that assigns participants to a tested intervention. Its 1,420 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (84% higher).
The record links to 0 conditions, and to 1 intervention - of which Interferon beta-1b (Betaseron, BAY86-5046) is the first listed.
NCT00459667 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00459667 about?
NCT00459667 is a clinical study titled "BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose". The BEYOND Follow-Up study will give patients who participated in the preceding BEYOND study the opportunity to continue treatment with the 500µg dose of interferon beta (IFNB) 1b and will further investigate the safety and tolerability profile of interferon beta 1b 500µg during longer-term treatmen...
What is the current status of trial NCT00459667?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,420 participants. The study started on 2007-05. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00459667?
The interventions under investigation include: Interferon beta-1b (Betaseron, BAY86-5046) (DRUG).
Who is sponsoring clinical trial NCT00459667?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00459667's enrollment target sits among peer trials
1,420 169th of 2000 higher than 1,832 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05890404 · 1,410 participants · NA
SGM Evidenced-Based Mental Healthcare Implementation
- NCT07042451 · 1,410 participants · NA
An Evaluation of the Pink Cloud Application in Post- Treatment Substance Use Disorder Support
- NCT07222566 · 1,410 participants · Phase 3
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- NCT05992935 · 1,405 participants · Phase 1
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia